Table 5.
Patents filed exclusively to reduce fast-fed variability.
| S. NO. | Patent | Title | Formulation Approach Used | Refs |
|---|---|---|---|---|
| 1. | US20110311594A1 | Controlled release compositions with reduced food effect. | Bilayered controlled release. | [154] |
| 2. | US20140212491A1 | Combination formulation of two antiviral compounds. | Solid dispersion. | [155] |
| 3. | CN103211759B | Puerarin nanocrystalline medical composition and preparation method thereof. | Nanocrystal. | [156] |
| 4. | CN102497857A | Nanostructured sildenafil base, its pharmaceutically acceptable salts and cocrystals, compositions of them, process for the preparation thereof, and pharmaceutical compositions containing them. | Cocrystals. | [157] |
| 5. | WO2015145157A1 | Pharmaceutical composition comprising pazopanib. | Nanoparticles. | [158] |
| 6. | JP2004523552A | Reduced food intake, fibrates with a fasting effect, the combination of statins. | Microparticles. | [159] |
| 7. | KR101300654B1 | Nanoparticulate fibrate formulations. | Nanoparticles. | [160] |
| 8. | US9504652B2 | Nanostructured aprepitant compositions, process for the preparation thereof, and pharmaceutical compositions containing them. | Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer nanoparticles. | [161] |
| 9. | ES2372746T3 | Stabilized microparticles fibrate. | Microparticles stabilized by surface active phospholipids. | [162] |
| 10. | US20090028935A1 | Carvedilol forms, compositions, and methods of preparation thereof. | Amorphous carvedilol phosphate salt and a complexing agent and controlled release of amorphous form. | [163] |
| 11. | WO2014009436A1 | Nanosuspension of abiraterone acetate. | Nanosuspension of abiraterone acetate. | [164] |
| 12. | CH707330A2 | Pharmaceutical compositions with reduced dose of fenofibrate. | A mixture of fenofibrate nanoparticles and micronized fenofibrate. | [165] |
| 13. | US9012511B2 | Nanoparticulate cinacalcet compositions. | Cinacacalcet nanoparticles. | [166] |
| 14. | US20080044486A1 | Controlled food effect composition. | Membrane lipids for controlled release. | [167] |
| 15. | WO2015145145A1 | Pharmaceutical composition comprising lapatinib. | Nanoparticles. | [158] |
| 16. | US20120135053A1 | Nanoparticulate telmisartan compositions and process for the preparation thereof. | Nanostructured Telmisartan. | [168] |
| 17. | US20130210794A1 | Nanostructured ezetimibe compositions, process for the preparation thereof, and pharmaceutical compositions containing them. | Nanostructured ezetimibe. | [169] |
| 18. | CN101180038A | Nanoparticulate corticosteroid and antihistamine formulations. | Antihistamine corticosteroid nanoparticles. | [170] |
| 19. | KR20080024213A | Nanoparticulate megestrol formulations. | Megesterol acetate nanoparticles. | [171] |
| 20. | JP2012530126A | Nanoparticulate Olmesartan medoxomil composition, method for its preparation, and pharmaceutical composition containing them. | Nano cocrystals. | [172] |
| 21. | ES2302925T3 | Nanoparticle compositions, kinase inhibitors, mitogen activated protein (MAP). | Nanoparticles. | [173] |
| 22. | US20090004262A1 | Nanoparticulate formulations and methods for the making and use thereof. | Cyclodextrin inclusion complex | [174] |
| 23. | JP2005535582A | Coated tablets. | Phospholipid applied to the surface of the fenofibrate microparticles. | [175] |
| 24. | CN101132768A | Nanoparticulate tacrolimus formulations. | Nanoparticles. | [176] |
| 25. | US20130303495A1 | Emulsion formulations. | SNEDDS, SMEDDS, and SEDDS | [177] |
| 26. | US20170112775A1 | Situ self-assembling pro-nanoparticle compositions and methods of preparation and use thereof. | Self-assembling pronanoparticles. | [178] |
| 27. | WO2014132134A1 | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same. | SNEDDS, SMEDDS, and SEDDS | [179] |